Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Total Current Liabilities (2020 - 2025)

P3 Health Partners (PIII) has disclosed Total Current Liabilities for 5 consecutive years, with $496.4 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Total Current Liabilities changed N/A year-over-year to $496.4 million, compared with a TTM value of $496.4 million through Dec 2024, changed N/A, and an annual FY2024 reading of $496.4 million, changed N/A over the prior year.
  • Total Current Liabilities was $496.4 million for Q4 2024 at P3 Health Partners, up from $405.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $496.4 million in Q4 2024 and bottomed at $175612.0 in Q1 2021.
  • Average Total Current Liabilities over 5 years is $221.6 million, with a median of $234.4 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 133376.64% in 2022, then increased 15.04% in 2023.
  • Year by year, Total Current Liabilities stood at $90.6 million in 2020, then tumbled by 99.57% to $390352.0 in 2021, then surged by 61809.25% to $241.7 million in 2022, then rose by 11.59% to $269.7 million in 2023, then surged by 84.09% to $496.4 million in 2024.
  • Business Quant data shows Total Current Liabilities for PIII at $496.4 million in Q4 2024, $405.3 million in Q3 2024, and $352.3 million in Q2 2024.